Waldenström's macroglobulinemia: Prognostic factors and recent therapeutic advances

Clinical and Experimental Medicine

Volumn 3, Issue 4, 2004, Pages 187-198

  Leblond, V ^a   Tournilhac, O ^b   Morel, P ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c Centre Hospitalier de LENS   (France)

Author keywords

Prognostic factors; Treatment; Waldenstr m's macroglobulinemia

Indexed keywords

CD20 ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; HEMOGLOBIN DETERMINATION; HUMAN; LEUKEMIA; MYELODYSPLASIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; SURVIVAL; WALDENSTROEM MACROGLOBULINEMIA;

COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 2342451910     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-004-0025-4     Document Type: Review

References (83)

1. Waldenström J (1944) Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia - a new syndrome? Acta Med Scand 117:216-247
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues; report of the Clinical Advisory Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
4. Owen RG, Johnson SA, Morgan GJ (2000) Waldenström's macroglobulinaemia: laboratory diagnosis and treatment. Hematol Oncol 18:41-49
5. Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS (2001) Waldenström macroglobulinemia development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 116:420-428
6. Wagner SD, Martinelli B, Luzzato L (1994) Similar patterns of Vk gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenström's macroglobulinemia and myeloma. Blood 83:3647-3653
7. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr (1998) Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 82:1078-1081
8. Dimopoulos MA, Alexanian R (1994) Waldenström's macroglobulinaemia. Blood 83:1452-1459
9. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M (2000) Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18:214-226
10. Garcia-Sanz R, Montoto S, Torrequebrada A, Coca AG de, Petit J, Sureda A, Rodriguez-Garcia JA, Masso P, Perez-Aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Blade J, Miguel JF; Spanish Group for the Study of Waldenstrom Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies) (2001) Waldenström's macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 115:575-582
11. Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, Bauters F, Fenaux P (1993) Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 11:1553-1558
12. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, Facon T, Dervite I, Bauters F, Najman A, Gramont A de, Wattel E (2000) Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858
13. Gobbi PG, Bettini R, Montecucco C, Cavanna L, Morandi S, Pieresca C, Merlini G, Bertoloni D, Grignani G, Pozzetti U, Caporali R, Ascari E (1994). Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 83:2939-2945
14. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B (2001) Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41-48
15. Kytsonis MC, Vassilakopoulos TP, Angelopoulou MK, Siakantaris P, Kontopidou FN, Dimopoulou MN, Boussiotis V, Gribabis A, Konstantopoulos K, Vaiopoulos GA, Fessas P, Kittas C, Pangalis GA (2001) Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol. 80:722-727
16. Bjorkholm M, Johansson E, Papamichael D, Celsing F, Matthews J, Lister TA, Rohatiner AZ (2003) Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study. Semin Oncol 30:226-230
17. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Therneau TM (2000) Waldenstrom's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742
18. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom macroglobulinemia. Semin Oncol 30:116-120
19. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B (2003) Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 30:220-225
20. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, Deliliers GL, Gobbi PG (2003). Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30:211-215
21. Stalnikiewicz L, Carrotte-Lefebvre I, Detourmignies L, Rose C, Cazin B, Leblond V, Morel P (2003) Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution - preliminary results on 101 patients. Semin Oncol 30:216-219
22. Schop RF, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Rajkumar SV, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Witzig TE, Fonseca R (2002) Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 132:55-60
23. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM (1999) Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 131:453-462
24. Buskard NA, Galton DA, Goldman JM, Kohner EM, Grindle CF, Newman DL, Twinn KW, Lowenthal RM (1977) Plasma exchange in the long-term management of Waldenstrom's macroglobulinemia. Can Med Assoc J 117:135-137
25. Avnstorp C, Nielsen H, Drachmann O, Hippe E (1985) Plasmapheresis in hyperviscosity syndrome. Acta Med Scand 217:133-137
26. Wicklund MP, Kissel JT (2001) Paraproteinemic neuropathy. Curr Treat Options Neurol 3:147-156
27. Gorson KC (1999) Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apheresis 14:149-153
28. Reinhart WH, Lutolf O, Nydegger UR, Mahler F, Straub PW (1992) Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med 119:69-76
29. Case DC, Ervin TJ, Boyd MA, Redfield DL (1991) Waldenström's macroglobulinemia: long term results with the M-2 protocol. Cancer Invest 9:1-7
30. Petrucci MT, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F (1989) Waldenström's macroglobulinemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 226:443-447
31. Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-453
32. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, Chott A, Gisslinger H, Knobl P, Lechner K, Jager U (2000) Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 79:556-559
33. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R (1993) Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118:195-198
34. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R (1994) Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698
35. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R (1994) 2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol 5:288-289
36. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL (1994) 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia. Nouv Rev Fr Hematol 36:317-320
37. Betticher DC, Hsu Schmitz SF, Ratschiller D, Rohr A von, Egger T, Pugin P, Stalder M, Hess U, Fey MF, Cerny T, Swiss Group for Clinical Cancer Research (SAKK) (1997) Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Br J Haematol 99:358-363
38. Liu ES, Burian C Miller HE, Saven A (1998) Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol 103:690-695
39. Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Hellmann A (2000) 2-Chlorodeoxyadenosine treatment of Waldenstrom's macroglobulinemia - the analysis of own experience and the review of literature. Med Sci Monit 6:740-745
40. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R (2003) 2-Chlorodeoxyadenosine alone or in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247
41. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood 75:1928-1931
42. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ (1993) Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 95:49-52
43. Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel JP, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N (1998) Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 16:2060-2064
44. Zinzani PL, Gherlinzoni F, Bendandi M, Zaccaria A, Aitini E, Salvucci M, Tura S (1995) Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol 54:120-123
45. Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia (2001) Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide- doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644
46. Levy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F, Harousseau JL, Remenieras L, Guibon O, Chevret S; French Cooperative Group on CLL and Macroglobulinemia (2001) Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. Leukemia 15:1466-1470
47. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M (1994) Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330:319-322
48. Treon PT, Wasi P, Emmanouilides C, Frankel SR, Kimby E, Lister A, Morel P, Kelliher A, Branagan A, Preffer F, Anderson KC (2002) Combination therapy with Rituximab and Fludarabine is highly active in Waldenstrom's macroglobulinemia (abstract). Blood 100:211
49. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P, Piccaluga PP, Pastano R, Leopardi G, Dizdari A, Motta MR, Rizzi S, Tura S (1999) Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid patients. Br J Haematol 105:775-779
50. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M, Bucalossi A, Marotta G, Tozzi M, Lauria F (2000) Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 37:157-161
51. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard EM, Samaha H, Rigal D, Coiffier B (1998) Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 103:235-242
52. Cheson BD (1995) Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448
53. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-Lopez AJ. (1999) Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 10:1525-1527
54. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324
55. Treon SP, Anderson KC (2000) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 27:79-85
56. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24:272-279
57. Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC (1999) Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol 26:97-106
58. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327-2333
59. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE (2001) Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 42:1329-1337
60. Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391-398
61. Rotoli B, De Renzo A, Frigeri F, Buffardi S, Marceno R, Cavallaro AM, Ruggeri P, Liso V, Musto P, Andriani A (1994) A phase II trial on alpha-interferon (aIFN) effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma 13:463-469
62. Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU (1988) Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenström's macroglobulinemia. Am J Hematol 29:1-4
63. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494
64. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, Economou O, Anagnostopoulos N, Panayiotidis P (2001) Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19:3596-3601
65. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97
66. Boussiotis VA, Freedman AS, Nadler LM (1999) Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol 36:209-216
67. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S (2001) High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström's macroglobulinemia. Bone Marrow Transplant 27:1027-1029
68. Anagnostopoulos A, Aleman A, Giralt S (2003) Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Semin Oncol 30:286-290
69. Dreger P, Glass B, Kuse R, Sonnen R, von Neuhoff N, Bolouri H, Kneba M, Schmitz N (1999). Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 106:115-118
70. Martino R, Shah A, Romero P, Brunet S, Sierra J, Domingo-Albos A, Fruchtman S, Isola L (1999) Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant 23:747-749
71. Mazza P, Palazzo G, Amurri B, Cervellera M, Manna N, Fellini G, Casulli F, Ghiggini M, Peluso A, Pricolo G, Prudenzano A, Stani L (1999) Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Bone Marrow Transplant 23:1273-1278
72. Munshi NC, Barlogie B (2003) Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 30:282-285
73. Mustafa M, Powles R, Treleaven J, Horton C, Sirohi B (1998) Total therapy with VAMP/CVAMP + high-dose melphalan and autograft for IgM lymphoplasmacytoid disease (abstract). Blood 92:281b
74. Seyfarth B, Sonnen R, Zeis M, Renk C, Schoch R, Schmitz N, Dreger P (2003) Failure of primary autologous stem cell transplantation to cure Waldenström's macroglobulinemia. Bone Marrow Transplant 31:S11-S86
75. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P (2003) Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 30:291-296
76. Yang L, Wen B, Li H, Yang M, Jin Y, Yang S, Tao J (1999) Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 24:929-930
77. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B, Munshi NC (1999) High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105:993-999
78. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Manhes G, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Guibon O, Travade P, for the French Cooperative Group on CLL (2002) Fludarabine plus cyclophosphamide as front line therapy in CLL durably impairs steady state G-CSF peripheral blood progenitor cells (PBPC) mobilization and harvest (abstract). Blood 100:827a
79. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T (2001) Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 28:609-611
80. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75-82
81. Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA (2002) Non-myeloablative transplantation. Hematology (Am Soc Hematol Educ Program) 392-421
82. Frankel SR (2003) Oblimersen sodium (G3139 Bcl-2 anti-sense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 30:300-304
83. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427